Stakeholders' Views of Alternatives to Prospective Informed Consent for Minimal‐Risk Pragmatic Comparative Effectiveness Trials

Publisher： John Wiley & Sons Inc

E-ISSN： 1748-720x|43|2|397-409

ISSN： 1073-1105

Source： THE JOURNAL OF LAW, MEDICINE & ETHICS, Vol.43, Iss.2, 2015-06, pp. : 397-409

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Generating Evidence for Comparative Effectiveness Research Using More Pragmatic Randomized Controlled Trials

By Mullins C. Daniel Whicher Danielle

PharmacoEconomics, Vol. 28, Iss. 10, 2010-10 ,pp. : 969-976

Adis International

Access to resources Recommend Favorite

Informed Consent and Informed Refusal

By WAGNER RICHARD F. TORRES ABEL PROPER STEVEN

Dermatologic Surgery, Vol. 21, Iss. 6, 1995-06 ,pp. : 555-559

Elsevier

Access to resources Recommend Favorite

Pharmacokinetic Studies in Infants Using Minimal-Risk Study Designs

Current Clinical Pharmacology, Vol. 9, Iss. 4, 2014-11 ,pp. : 350-358

Bentham Science Publishers

Access to resources Recommend Favorite

Inclusion of Patients with Severe Mental Illness in Clinical Trials: Issues and Recommendations Surrounding Informed Consent

By Welie Sander P.K. Berghmans Ron L.P.

CNS Drugs, Vol. 20, Iss. 1, 2006-01 ,pp. : 67-83

Adis International

Access to resources Recommend Favorite

Private Manufacturers' Thresholds to Invest in Comparative Effectiveness Trials

By Basu Anirban Meltzer David

PharmacoEconomics, Vol. 30, Iss. 10, 2012-10 ,pp. : 859-868

Adis International

Access to resources Recommend Favorite